Psoriasis is a medical condition in which the skin of the body is affected at a multisytemic level. Patients with moderate to severe psoriasis have a considerably reduced quality of life as a result of their disease. For morphological indicators, the Psoriasis Area Severity Index (PASI) test is one of the methods for indicating the severity of the illness. An imbalance between pro-oxidants and antioxidants in our bodies causes oxidative stress and plays a crucial role in the pathophysiology of chronic inflammatory diseases like psoriasis(1). It has been considered that antioxidant treatment can be an effective therapeutic option. The goal of this clinical investigation was to see if there was a link between the percentage change in quality of life and the clinical severity of psoriasis during a 12-week period among Iraqi psoriatic patients. Over the course of 3 months, 24 psoriatic patients (9 females and 15 males) ranging in age from 17 to 72 years participated in a prospective double-blinded clinical experiment. Two groups of participants were formed. A biological medicine (adalimumab) and a placebo was given to group A (n = 11), whereas group B (n = 13) received 100 mg CoQ10 adjuvant therapy in addition to the biological medication already provided. The Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI) were used to examine patients (DLQI). Treatment with both biological and adjuvant CoQ10 therapy showed a substantial Effect of CoQ10 Administration to Psoriatic Iraqi Patients on Biological Therapy e53
Background:Oral recurrent aphthous stomatitis is the most common disease of the oral cavity. The underlying etiology remains unclear, and no curative treatment is available. Zinc is essential and useful for normal growth and tissue repair, zinc acts as an integral part of several enzymes important to protein and carbohydrate metabolism.Objectives:The presentstudy aimedto use systemic drug used zinc oral dispersible tablet (20mg).Illnesses related to the oral cavity by studyingits effects in oral recurrent aphthous stomatitis major clinical type (ORAS), this systemic therapy is not indicated in such situations among other drugs.Methods:In this study patientspresented with (ORAS) ulceration lesions were treated with zinc oral dispersible tablet (20mg) administered orally once daily after meal. The dispersible tablet was administered orally once daily for 14 days, 52 patients (36 males and 16 females aged between 28-30)with biopsy-confirmed aphthous ulceration of the lesions area, divided into two groups;group A, 28 patients were randomly assigned to receive zinc oral dispersible tablet, 20 mg/dayonce per day, and group B;24 patients with oral placebo daily for 14 days.Results: The results showed that administering of zinc oral dispersible tablet once per day accelerated the healing process within a short time period (8 days) without complications or disfigurement in all patients.Group A, 22 patients, (healing rate 0.66%) of 28 patients were used zinc oral dispersible tablet (20mg) doses administered orally had complete healing of aphthous ulcers at period time eight days of clinical investigation evaluation and weight increase rate by 0.32% kg during the time period of the study, compared with group B, only8 patients (healing rate 0.21%) of 24 placebo-randomized patients eating ability caused by oral cavity aphthous ulceration were improved markedly and had a weight loss rate by 0.53% kg.Conclusion:In this study showed that, the zinc oral dispersible tablet treatment was effective in healing of the major type aphthous ulceration and the end-points of the study were complete healing and absence of any discomfortpain while eating within a short period of treatment.
Psoriasis refers to a medical condition involving long-term infl ammation, high insulin resistance, obesity and a likelihood of cardiovascular disease. Objective: This paper attempts to fi nd out if the addition of metformin to biological therapy has the benefi cial eff ect of increasing insulin sensitivity in moderate to severe Iraqi psoriatic patients. Subjects and Methods: The experimental group comprises 24 patients suff ering from moderate to severe psoriasis. They were randomly selected into two groups: group A comprises 13 psoriatic patients treated with 40 mg of adalimumab twice monthly for 12 weeks. While group B contains 11 psoriatic patients treated with 40 mg of adalimumab twice monthly and a single daily dose of 850 mg of metformin for 12 weeks. The psoriasis area and severity index (PASI), glycosylated hemoglobin (HbA1c), body mass index (BMI), as well as insulin-resistance parameters, which include fasting blood glucose (FBG) and fasting serum insulin (FSI) are estimated for each patient before and after completion of therapy. Results: The two groups showed a signifi cant reduction in insulin resistance. Nonetheless, group B showed greater reduction. Furthermore, the PASI score of the two groups exhibited improvement, but group B exhibited a higher percentage improvement than group A, and the diff erence was signifi cant (p <0.05). Conclusion: This study demonstrates that adding a single daily dose of 850 mg of metformin has a more benefi cial eff ect on insulin resistance (IR) in psoriasis patients than using only biological therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.